Lipid Nanovesicles by Microfluidics: Manipulation, Synthesis, and Drug Delivery

Abstract

Lipid nanovesicles, including endogenous exosomes and synthetic lipid nanoparticles, have shown great potential in disease diagnostics, drug delivery, and cancer biology. Naturally secreted nanovesicles are promising biomarkers for early detection of cancers in vitro. Synthetic nanovesicles serve as robust drug delivery systems with enhanced tumor targeting in vivo. Microfluidic platforms with features of excellent flow control and rapid mixing are exploited as versatile tools for studying lipid nanovesicles of small sizes and delicate structures. Here, an overview of microfluidics for precise manipulation and synthesis of lipid nanovesicles is provided. The mechanisms of isolation and detection of exosomes in microfluidics, as well as the clinical utility of exosomes for cancer diagnosis, are discussed. Several microfluidic designs for controlled assembly of a variety of lipid nanovesicles are highlighted. Opportunities and outstanding challenges of microfluidics‐based investigation of lipid nanovesicles are discussed.

Synergistic Amplification of Oxidative Stress–Mediated Antitumor Activity via Liposomal Dichloroacetic Acid and MOF‐Fe2+

“…Liposome is a widely used drug delivery system due to its good biocompatibility, size, and hydrophobic and hydrophilic character, and can selectively deliver active molecules to the site of action, making it suitable for multiple clinical applications . For example, Doxil, liposomal formulation of doxorubicin (DOX), is a top choice for treating solid tumors in clinic, according to its ability to reduce DOX cardiotoxicity .…”

Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source

“…This nature of EVs shed light on future DDS, although EVs are also accumulated in liver, and other important organs, such as pancreas. Nevertheless, compared with other delivery systems, such as adenoviruses, lentiviruses, retroviruses, lipid transfection reagents, and lipid nanoparticles, EV-based DDS is well recognized to have limited immunogenicity and cytotoxicity (van der Meel et al, 2014;Liu et al, 2019;Yang et al, 2019).…”

Advances in Exosomes‐Based Drug Delivery Systems

“…Recently, microfluidic devices are used in exosome isolation [ 99,100 ] ( Figure 5 ). Their basis is the controlled handling of the sample through capillary tubes associated to different isolation mechanisms.…”